A Phase 2 Study to Evaluate the Effectiveness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma : A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2019) vom: 16. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-10-2019, Last updated: 2022-11-24 |
|---|
| ICTRP ID: |
EUCTR2018-002556-32-ES |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CTG004310969 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG004310969 | ||
| 003 | DE-627 | ||
| 005 | 20230425170511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210507s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG004310969 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2018-002556-32-ES | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)ADCT-301-201 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)121912 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)2018-002556-32-BE | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Phase 2 Study to Evaluate the Effectiveness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma |b A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-10-2019, Last updated: 2022-11-24 | ||
| 650 | 4 | |a Medical Condition: Relapsed or Refractory Hodgkin Lymphoma MedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0Level: PTClassification code 10020267Term: Hodgkin's disease refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: PTClassification code 10020234Term: Hodgkin's disease mixed cellularity refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: PTClassification code 10020233Term: Hodgkin's disease mixed cellularity recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2019) vom: 16. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:16 |g month:12 |
| 856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002556-32 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 16 |c 12 | ||